Farxiga (dapagliflozin) is not only considered safe for stage 3 kidney disease, it is specifically approved by the FDA to treat it. The landmark clinical trial that led to its approval enrolled patients with eGFR values between 25 and 75, which covers the full range of stage 3 CKD (eGFR 30 to 59) and extends into stages 2 and 4. International kidney disease guidelines now recommend SGLT2 inhibitors like Farxiga as a core part of CKD treatment for patients with an eGFR of 20 or above.
Why Farxiga Is Recommended for Stage 3 CKD
Farxiga was approved to reduce the risk of kidney function decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD at risk of progression. Stage 3 kidney disease sits squarely in the middle of the eGFR range studied in clinical trials, meaning the evidence for its safety and effectiveness is strongest in exactly this group.
The 2024 KDIGO guidelines, which set the global standard for kidney disease management, recommend SGLT2 inhibitor therapy for adults with CKD who have significant protein in their urine (a key marker of progression risk), with or without diabetes. If you have type 2 diabetes alongside stage 3 CKD, the recommendation is even broader: SGLT2 inhibitors are advised for anyone with an eGFR of 20 or above.
How Farxiga Protects the Kidneys
Farxiga works differently from most kidney medications. It reduces the pressure inside the tiny filtering units of the kidney (called glomeruli) by restoring a natural feedback loop that gets disrupted in CKD. Essentially, the drug causes the blood vessel entering the kidney’s filter to constrict slightly while relaxing the vessel leaving it. This lowers the strain on the filter itself, slowing the damage that causes CKD to worsen over time.
This pressure-lowering effect means your eGFR may dip slightly when you first start the medication. That initial drop is expected and is actually a sign the drug is working. Guidelines recommend continuing Farxiga through this dip as long as you tolerate it, and the medication can be continued even if kidney function later declines below the threshold for starting it.
Dosing at Different eGFR Levels
The standard dose is 10 mg once daily, regardless of whether your eGFR is 60 (early stage 3) or 30 (late stage 3). Here’s how the thresholds break down:
- eGFR 45 or above: 10 mg daily, effective for both kidney protection and blood sugar control if you have diabetes.
- eGFR 25 to 44: 10 mg daily, still protective for the kidneys, but no longer effective enough to meaningfully lower blood sugar on its own.
- eGFR below 25: Starting the drug is not recommended, but if you’re already taking it, you can continue.
For stage 3 CKD specifically, you fall well within the range where Farxiga can be safely started. No dose adjustment is needed.
Side Effects to Watch For
The most common side effect is mild genital yeast infections in both men and women. These occur because the drug works by causing your kidneys to excrete more sugar into the urine, which creates an environment where yeast can thrive. Topical antifungal treatments resolve this easily, and for most people it’s a one-time issue.
The clinical trial data did not show an increased risk of urinary tract infections or low blood sugar, which are concerns many patients have when starting the medication.
A rare but serious risk is a type of metabolic acidosis where dangerous levels of ketones build up in the blood even though blood sugar remains normal. This is called euglycemic ketoacidosis, and it most commonly occurs during acute illness, dehydration, or infection. Symptoms include unexplained fatigue, nausea, vomiting, abdominal discomfort, and confusion. The risk is higher in older adults and in people who are acutely unwell.
Combining Farxiga With Other CKD Medications
Most people with stage 3 CKD are already taking other medications that affect kidney function or blood pressure, such as ACE inhibitors, ARBs, or diuretics. Farxiga can be used alongside these, but the combination increases the risk of dehydration and low blood pressure. This risk is highest in older adults, people with already low blood pressure, and those taking loop diuretics.
If you take potassium-sparing diuretics or medications that affect the renin-angiotensin system (ACE inhibitors and ARBs), there’s also a slightly elevated risk of high potassium levels. Your doctor will typically check your bloodwork after starting Farxiga to make sure your electrolytes stay balanced.
What to Do When You’re Sick
One of the most important practical things to know about Farxiga is the “sick day” rule. If you develop an illness that causes vomiting, diarrhea, or significant dehydration, you should temporarily stop taking Farxiga until you’ve recovered and are eating and drinking normally again. This applies to several CKD medications at once: SGLT2 inhibitors, ACE inhibitors, ARBs, diuretics, metformin, and NSAIDs should all be paused during dehydrating illness. The acronym healthcare providers use for this group is SADMANs. Continuing these medications while dehydrated raises the risk of acute kidney injury and, in the case of Farxiga, ketoacidosis.
Ask your prescriber for a written sick day plan so you know exactly which of your medications to hold and when to restart them. This is especially important for people managing stage 3 CKD, where the kidneys have less reserve capacity to handle additional stress.